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Abstract 
Background: Refractory cardiac arrest (CA) occasionally develops in patients after cardiac surgery.
Objective: To examine the clinical outcomes of extracorporeal cardiopulmonary resuscitation (ECPR) in adult 
patients with post-cardiotomy CA.
Methods: This was a retrospective study of the 9-year experience (from January 2004 to May 2012) of the Beijing 
Anzhen Hospital with ECPR in adult patients with post-cardiotomy CA. At this hospital, a dedicated ECPR team is 
available 24/7 for emergency cases requiring ECPR. Demographic data, biochemical data, survival, morbidity, and 
complications were examined before, during, and after ECPR. Outcomes were compared between survivors and 
non-survivors.
Results: Twenty-four adult patients (19 men and 5 women; mean age: 59.3 ± 11.9 years) received ECPR support for 
post-cardiotomy CA. The cardiac surgery procedures included coronary artery bypass grafting (n = 20, 83.3 %), val-
vular surgery alone (n = 2, 8.3 %), and correction of congenital heart defects (n = 2, 8.3 %). The mean extracorporeal 
membrane oxygenation (ECMO) duration was 115.23 ± 70.17 h. Twenty-one patients received ECPR after intra-aortic 
balloon pump, and three patients received ECPR directly. The main cause of mortality was multiple system organ fail-
ure (n = 12, 50.0 %). Approximately one-half of non-survivors had severe neurologic impairments. Among 16 patients 
who were weaned off ECMO support, eight patients survived to hospital discharge.
Conclusions: ECPR can be effective for partial cardiopulmonary support to resuscitate adult patients suffering from 
refractory CA after cardiac surgery. Improvement in outcomes of patients who received ECPR requires a multidiscipli-
nary approach to protect organ function and limit organ injury before and during cardiac support.
Keywords: Refractory cardiac arrest, Extracorporeal cardiopulmonary resuscitation, Cardiac surgery, Mean 
extracorporeal membrane oxygenation
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Background
Cardiac arrest (CA) is a major health concern, and sur-
vival rates remain very low despite early access to emer-
gency medical care and continual improvements in 
treatment strategies [1]. The incidence of myocardial dys-
function after cardiac surgery is 3–5 %, and most patients 
can be managed using inotropes or intra-aortic balloon 
counterpulsation [2]. Nevertheless, about 1  % of these 
patients will experience refractory cardiac dysfunction 
and will need advanced mechanical support [3, 4].
Extracorporeal cardiopulmonary resuscitation (ECPR) 
was introduced in the 1960s to improve the efficacy and 
outcomes of cardiopulmonary resuscitation (CPR) when 
CPR fails [5]. Chen et al. [6] have used ECPR since 1994 
and suggested that prolonged CPR rescue by extracor-
poreal membrane oxygenation (ECMO) might provide an 
acceptable survival rate and outcome in survivors, which 
was supported by subsequent studies [4, 7–10]. The 
International Liaison Committee on Resuscitation stated 
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that ECPR might improve outcomes after CA compared 
with standard CPR in cases of cardiogenic shock and CA 
when there is an underlying circulatory disease amenable 
to immediate corrective intervention [11].
Despite significant risks, many institutions accumu-
lated successful experiences with ECPR in adult patients 
[9, 12, 13]. The present study reviewed the 9-year expe-
rience of the Beijing Anzhen Hospital with ECPR per-
formed in adult patients with post-cardiotomy CA. The 
aim was to observe outcomes during and after ECPR, 
and to identify factors that could affect the survival rate 
and weaning from ECMO. The hypothesis was that ECPR 




This was a retrospective study of the 9-year experience 
(from January 2004 to May 2012) of the Beijing Anzhen 
Hospital with ECPR in adult patients with post-cardi-
otomy CA. CA was defined as the need for chest com-
pressions or direct, open-chest cardiac massage [14, 
15]. Inclusion criteria were: (1) cardiac origin of CA; (2) 
received ECMO after undergoing cardiac surgery in the 
hospital; (3) no sustained return of spontaneous circu-
lation after at least 10–15 min; and (4) no obvious con-
traindication to ECPR including terminal malignancy, 
irreversible multi-organ failure, or severe neurologic 
injury. Exclusion criteria were: (1) patients who could not 
be weaned off cardiopulmonary bypass (CPB) after sur-
gery owing to myocardial stunning and who were then 
shifted to ECMO; or (2) patients with progressive dete-
rioration and who urgently needed ECMO support with-
out cardiac massage or boluses of epinephrine.
As required by hospital policies, all cardiac surgery 
patients must sign an informed consent form with 
detailed explanations of the surgery as well as all optional 
procedures (e.g., ECPR) prior to the operation. This study 
was approved by the Capital Medical University in Bei-
jing, China. All ECPR patients were identified from data 
collected at the Beijing Anzhen Hospital, and individual 
consent was waived by the committee because of the ret-
rospective nature of the study. Data are available upon 
request addressed to the ethical committee of the Beijing 
Anzhen Hospital.
ECMO team and organization
At the Beijing Anzhen Hospital, there is a dedicated 
ECMO rapid response team that is directly supervised by 
the Cardiac Intensive Care Center of the institution. This 
team consists of cardiac surgeons, intensive care unit 
(ICU) physicians, ECMO specialists and nursing staff. 
Per protocol, conventional CPR is managed by a fellow 
or cardiac surgeon, attending physician, ICU physicians, 
and nursing staff, all of whom provide assistance and 
consultation to the ECMO specialists. Those full-time 
ECMO specialists are not only responsible to help set up 
the ECMO circuit, but also responsible for ECMO care. 
The ECMO coordinator is on-call 24/7, and immediately 
available to return to the hospital to initiate ECPR.
ECMO equipment and management
The ECMO cart includes cannulas, ECMO accessories, 
surgical instruments, suture materials, surgical drapes, 
and all necessary supplies. The ECMO system consists 
of a Quadrox-D hollow-fiber oxygenator with BIOLINE 
coating, a Rotaflow centrifugal pump (Maquet, Hir-
rlingen, Germany) with heparin-coated circuit tubing, 
a Sechrist oxygen/air blender, and a water heater/cooler 
(Sarns, Minneapolis, MN). Carmeda heparin-coated can-
nulas (Medtronic, Minneapolis, MN, USA) were used in 
all patients. Systemic heparinization was not needed on 
the day ECMO support was initiated; no hemorrhage, 
surgical bleeding, or oozing was noted due to heparin 
coating of the bioactive surface. The circuit was assem-
bled and ready to be primed using acetated Ringer’s solu-
tion. All patients received venous-arterial (VA) ECMO 
for ECPR.
The femoral route was always preferred instead of the 
open sternotomy route for VA ECMO support because 
the wound of an open sternotomy increases the risk of 
infection and hemorrhage, and access via an open ster-
notomy also makes nursing care more difficult. If the 
femoral vascular status was poor, transthoracic cannu-
lation was used. For femoral cannulation, the modified 
open Seldinger method was used [16]. The femoral ves-
sels were dissected, and the cannulas were inserted with a 
guide wire under direct vision. This method was particu-
larly useful during CPR when the femoral pulse was not 
palpable.
Cardiac massage was temporarily stopped for a few 
seconds when the vessel was punctured and the guide 
wire was introduced. Purse-string sutures were placed 
around the cannula to prevent hemorrhage. For distal 
extremity perfusion, an anterograde reperfusion catheter 
was inserted into the distal femoral artery.
When ECPR was initiated, the ECMO flow was set 
to achieve adequate blood pressure (approximately 
60  mmHg) with adjustments using vasopressors and 
reversal of metabolic acidosis. Mixed venous oxygena-
tion saturation was maintained to >65 % and hematocrit 
to  >30  %. A constant positive end-expiratory pressure 
was maintained to keep the alveoli open. Core body tem-
perature was kept at 34–35  °C using the heater-cooler 
load in the ECMO circuit for at least 24  h for cerebral 
protection in post-resuscitation care [17]. Electrolytes 
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were corrected to the normal range, while the blood 
glucose was maintained to <200 mg/dl. To address this, 
fentanyl was used to sedate the patients after return 
of spontaneous eye movement; and serum lactate lev-
els were measured to confirm the reversal of anaerobic 
metabolism. Low-dose heparin was infused to keep the 
activated clotting time between 180 and 220  s. High-
dose catecholamine was slowly tapered down. If heart 
contractility improved based on echocardiography, if 
lung function was adequate, and if the shock status was 
reversed, an attempt was made to wean the patient from 
ECMO [18].
Data collection
Demographic data including age, gender, height, weight, 
primary diagnosis, and pre-ECMO co-morbidities were 
recorded. The medical record consisted of CPR dura-
tion, ECMO duration, and ECMO-related complications. 
ECMO duration was defined as the time of ECMO flow 
initiation to the time of ECMO flow discontinuation 
[19]. Laboratory data included arterial blood gas (ABG) 
obtained pre-ECPR and 24 h after initiating ECPR, coag-
ulation tests, and biochemical indices such as blood urea 
nitrogen (BUN), creatinine (Cr), aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), total 
bilirubin (TBIL), direct bilirubin (DBIL), MB fraction of 
creatinine kinase (CK-MB), and lactic acid (LAC).
The clinical outcomes in the survival and non-survival 
groups were examined, and the outcomes of weaning 
from ECMO were also compared.
Statistical analysis
All data were analyzed using SPSS 18.0 (SPSS Inc., Chi-
cago, IL, USA). The Chi-square test was used for cat-
egorical variables. Continuous variables were tested for 
normality using the Kolmogorov–Smirnov test. The Wil-
coxon rank-sum test was used for non-normally distrib-
uted variables. Normally distributed continuous variables 
were compared using the Student’s t test. All tests were 




Between January 2004 and May 2012, 150 patients 
underwent cardiac surgery and received ECMO. Twenty-
four adult patients (19 males and 5 females) suffered 
from refractory CA and received ECPR. Mean age was 
59.3  ±  11.9  years (range 23–76). Most patients were 
male (n = 19, 79.2 %). Of these 24 patients, 16 (66.7 %) 
were weaned from ECMO, 8 (33.3  %) survived to hos-
pital discharge, and 16 (66.7  %) patients died. Diagno-
sis (P  =  0.53) and ECPR location (P  =  0.77) were not 
different between survivors and non-survivors (Table 1). 
Figure 1 shows the yearly distribution of ECPR cases and 
the survival-to-discharge ratio during the review period.
Characteristics of ECMO
The median duration of CPR from CA to the start of 
ECMO was 36.0 min (range 14–115). Mean duration of 
ECMO was 115.23  ±  70.17  h. Mean hospital stay was 
25  days. ECPR was performed in 23 of the 24 patients 
using the femoral route. The open sternotomy route had 
to be used in one patient because of severe plaques in the 
femoral arteries; he was successfully weaned off ECMO, 
but died of multiple system organ failure (MSOF).
Comparison between survivors and non‑survivors
Tables  2 and 3 show the comparison between the sur-
vivors at discharge and the non-survivors. The demo-
graphic and biochemical data were not different between 
survivors at discharge and non-survivors before, during, 
and after ECMO. In addition, the duration of CPR and 
ECMO were similar in the two groups. Mean hospital 
stay for the non-survivors was 17.7  ±  9.5  days includ-
ing 12.5 ± 8.1 days in the ICU. Mean hospital stay for the 
survivors was 41.0 ± 12.2 days including 8.7 ± 5.5 days in 
the ICU (Table 3).
Among the non-survivors, 12 of 16 (75  %) patients 
died from MSOF. The incidence of MSOF was signifi-
cantly higher in non-survivors (P = 0.001) (Table 3). One 
patient died from massive hemorrhage, despite undergo-
ing a second operation. One patient had a left ventricular 
assistance device implanted concurrently, and could not 
be weaned from ECMO. Eight non-survivors had severe 
neurologic impairments. In addition, one survivor had 
neurologic complications (right lower extremity paraly-
sis), and he was transferred to another specialized hospi-
tal for further treatments.
Table 1 Clinical characteristics
CAD coronary artery disease, AR aortic regurgitation, VSD ventricular septal 
defect, PH pulmonary hypertension, CPR cardiopulmonary resuscitation, ECPR 
extracorporeal cardiopulmonary resuscitation, ICU intensive care unit





Cardiac disease, n (%)
 CAD 8 (100.0) 12 (75.0) 0.530
 AR 0 2 (12.5)
 VSD + PH 0 2 (12.5)
ECPR location, n (%)
 Operation room 3 (37.5) 6 (37.5) 0.770
 ICU 5 (62.5) 9 (56.2)
 Ward 0 1 (6.3)
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Survival after weaning from ECMO
Sixteen patients who were weaned from ECMO were 
further divided into two groups: survivors at discharge 
(n  =  8) and non-survivors after weaning from ECMO 
(n  =  8). Some patients’ characteristics were different 
between survivors at discharge and non-survivors: dura-
tion from the end of surgery to CPR (median 4.5 vs. 95 
min; P = 0.024), peak creatinine levels (158.91 ± 113.48 
vs. 309.11 ± 139.27 μmol/L; P = 0.033), and peak BUN 
levels (median 18.04 vs. 29.09  mmol/L; P  =  0.046) 
(Table 3).
Comparison between non‑survivors during ECMO 
and non‑survivors after weaning ECMO
Non-survivors were divided into two groups (non-
survivors of weaning ECMO and non-survivors dur-
ing ECMO). Compared with patients who died during 
ECMO, patients who died after weaning showed a longer 
time between surgery and CPR [median 95.0 (248.0) vs. 
2.5 (93.0) h, P  =  0.034], higher pre-ECPR TBIL levels 
[median, 15.80 (30.30) vs. 8.83 (4.73) µmol/L, P = 0.011], 
higher frequency of consciousness during ECMO (87.5 
vs. 12.5 %, P = 0.010), shorter ECMO duration [median, 
111.4 (41.1) vs. 127.5 (128.0) h, P  =  0.012], and lower 
peak CKMB levels [median 176 (96) vs. 283 (405) U/L, 
P = 0.035] (Table 4).
Fig. 1 Yearly distribution of ECPR cases
Table 2 Patients’ characteristics before  ECMO according 
to survival
Results are presented as n (%), mean ± SD or median (interqartile range)
ECMO extracorporeal membrane oxygenation, DM diabetes mellitus, IABP intra-
aortic balloon pump, EF ejection fraction, BUN blood urea nitrogen, TBIL total 










Hyperlipidemia 5 (52.5) 8 (50.0) 0.679
DM 2 (25.0) 4 (25.0) 1.000
Hypertension 2 (25.0) 8 (50.0) 0.388
Previous cerebral 
infarction
0 3 (18.8) 0.526
CPR duration (min) 30.00 (152.00) 43.00 (107.00) 0.976
Hypothermia 2 (25.0) 5 (31.3) 1.000
Pre-ECMO IABP 8 (100.0) 13 (81.3) 0.439
Distal perfusion 5 (52.5) 13 (81.3) 0.362
EF (%) 51.50 ± 14.82 52.00 ± 14.38 0.937
pH 7.35 ± 0.12 7.35 ± 0.13 0.909
PO2 (mmHg) 268.05 ± 117.89 174.89 ± 113.60 0.075
PCO2 (mmHg) 36.03 ± 5.97 39.44 ± 11.36 0.437
HCO3ˉ (mmol/L) 20.65 ± 4.17 21.69 ± 6.53 0.686
Base excess 
(mmol/L)
−4.75 (4.93) −4.70 (7.78) 0.624
TBIL (μmol/L) 11.03 (4.62) 11.16 (15.63) 0.580
DBIL (μmol/L) 3.55 (1.54) 3.59 (3.29) 0.326
Table 3 Patients’ characteristics during  and after  ECMO 
according to survival
Results are presented as n (%), mean ± SD or median (interquartile range)
IABP intra-aortic balloon pump, ECMO extracorporeal membrane oxygenation, 







ECMO duration (h) 115.50 (22.00) 109.72 (69.62) 0.602
Kept pre-ECMO IABP 5 (62.5) 10 (62.5) 1.000
New intra-ECMO IABP 0 1 (6.3) 1.000
Cardiac tamponade 0 4 (25.0) 0.262
Re-CPR 2 (25.0) 5 (31.3) 1.000
Bacterial infection 5 (52.5) 6 (37.5) 0.390
Pneumorrhagia 0 3 (18.8) 0.526
Gastrointestinal 
bleeding
2 (25.0) 3 (18.8) 1.000
Urinary bleeding 0 2 (12.5) 0.536
Hemoglobinuria 1 (12.5) 3 (18.8) 1.000
Creatinine ≥3 μmol/L 1 (12.5) 8 (50.0) 0.178
Hemodialysis 1 (12.5) 6 (37.5) 0.352
Distal ischemia 1 (12.5) 1 (6.3) 1.000
Infection 5 (52.5) 6 (37.5) 0.390
MSOF 0 12 (75.0) 0.001
Brain death 0 2 (12.5) 0.536
Ventilation duration 
(h)
165.00 (304.00) 146.94 (91.357) 0.540
ICU duration (days) 12.50 (8.10) 8.77 (5.46) 0.158
Initiation flow (ml/
min/kg)
47.20 ± 13.62 50.01 ± 11.60 0.603
Highest Lactate 
(mmol/L)
15.25 (4.00) 12.74 (4.55) 0.444
Highest creatinine 
(μmol/L)
77.25 (24.79) 85.00 (23.60) 0.581
Peak BUN (nmol/L) 18.04 ± 6.18 30.39 ± 25.78 0.086
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Complications
Eleven patients (45.8  %) developed bacterial infections. 
Clinical complications of ECPR such as cardiac tampon-
ade, brain lesion, pneumorrhagia, urinary tract bleeding, 
and persistent hemorrhage only occurred in the non-sur-
vivors. Mechanical complications such as thrombosis in 
the pump head or distributed within the extracorporeal 
circulation also occurred only in the non-survivor group.
Discussion
The objective of the present study was to examine the 
clinical outcomes of ECPR in adult patients with post-
cardiotomy refractory CA. Results showed that among 
24 adult patients who received ECPR support for post-
cardiotomy refractory CA, the mean ECMO duration 
was 115.23  ±  70.17  h. The cardiac surgery procedures 
included coronary artery bypass grafting (83.3  %), val-
vular surgery alone (8.3  %), and correction of congeni-
tal heart defects (8.3  %). Twenty-one patients received 
ECPR after intra-aortic balloon pump (IABP) and three 
patients received ECPR directly. The main cause of mor-
tality was multiple system organ failure (50.0 %). Approx-
imately one-half of non-survivors had severe neurologic 
impairments. Among 16 patients who were weaned from 
ECMO, eight patients were alive at discharge.
ECPR provides a period of stability for the resolution 
of the underlying problems that led to refractory CA in 
the first place [20]. Because of the cost, complexity of the 
technique, and required resources, ECPR is not offered 
in all centers. However, ECPR is recommended for CA 
that is refractory to initial resuscitation attempts if the 
condition leading to CA is reversible or amenable to 
heart transplantation, if excellent conventional CPR has 
been performed after no more than a few minutes of CA, 
and if the institution is able to rapidly perform ECMO 
[21].
In the present study, CABG (83.3  %) was the most 
common surgical procedure that was performed in 
patients who developed CA and required ECPR, which 
is in agreement with a previous report [22]. It is unclear 
whether or not patients with coronary artery diseases or 
other cardiac diseases are more sensitive to reperfusion 
injury of ischemic tissue, and whether or not they are 
more susceptible to the possibility of myocardial injury 
following ECPR [17]. Further studies are necessary to 
assess this point.
In the study by Lan et  al. [22], the survival rate was 
30.1  %, while the study by Flecher et  al. [23] reported 
survival of 41–45  %. According to the Extracorporeal 
Life Support Organization (ELSO) registry, the sur-
vival rate of adult patients receiving ECPR for CA was 
28 % between 1990 and 2012 [24]. Although the survival 
rate in the present study was higher, it was comparable 
to previous studies [9, 25]. However, the ELSO registry 
includes all patients receiving ECPR, while the present 
study included patients who underwent cardiac surgery 
only. Another study in a population of patients that was 
similar to the present study showed a survival of only 
15 % [26]. As in the study by Lan et al. [22], gender did 
not affect survival at discharge.
In the present study, the duration of CPR and ECMO 
were also similar to those of Huang et al. [19], and did not 
Table 4 Comparison between non-survivors after weaning from ECMO and non-survivors during ECMO
Results are presented as n (%), mean ± SD or median (interquartile range)
ECPR extracorporeal cardiopulmonary resuscitation, CKMB creatinekinase-MB, TBIL total bilirubin
* P < 0.05






 Age (years) 59.8 ± 17.7 61.5 ± 4.5 0.790
 Gender (male/female) 4/4 8/0 0.077
 Duration from operation to CPR (h) 95.00 (248.00) 2.50 (93.00) 0.034*
 Pre-ECPR TBIL (μmol/L) 15.80 (30.30) 8.83 (4.73) 0.011*
Intra-ECMO
 Awake 7 (87.5) 1 (12.5) 0.010*
 ECMO duration (h) 111.38 (41.08) 127.50 (128.00) 0.012*
 Peak CKMB (U/L) 176.02 (95.88) 282.50 (405.00) 0.035*
 Peak lactate (mmol/L) 12.79 (6.35) 20.00 (4.60) 0.067
 Peak creatinine (μmol/L) 268.05 ± 117.89 174.89 ± 113.60 0.051
 Lactate 24 h after ECPR (mmol/L) 4.65 ± 3.90 6.10 (10.10) 0.074
 Bleeding at intubation site 0 4 (50.0) 0.077
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differ significantly between survivors and non-survivors. 
In our hospital, the ECMO preparation room is next to 
the ICU and operating room; therefore, ECMO prepa-
ration and initiation are very timely if CA occurs. Nine 
patients (37.5 %) suffered from CA at the end of the sur-
gery, and there was no need to move them before initiat-
ing ECPR. Fourteen patients (58.3 %) suffered from CA in 
the ICU. In the present study, set up time for ECPR (from 
notification of the ECMO team to running the ECMO 
pump) was approximately 30  min. According to recent 
reports on CPR, the sooner ECPR is initiated, the earlier 
systemic perfusion is improved, and the higher the sur-
vival rate [19, 27]. In the present study, there was a trend 
for higher mortality rates with increasing CPR duration.
An IABP is the first option due to its relative non-inva-
siveness and low cost compared with ECMO. In contrast, 
ECMO is the better choice for CA not amenable to IABP 
support alone. Twenty-one patients (87.5  %) were New 
York Heart Association (NYHA) class III or IV prior to 
surgery, and they had been using a preoperative or intra-
operative IABP. Refractory CA eventually occurred in 
this population after surgery because of the inefficacy of 
IABP. For such patients, ECMO alone or in combination 
with IABP might be used as soon as possible, but further 
studies are necessary to evaluate this approach.
According to several published studies, sepsis with 
MSOF has been associated with poor outcomes [22]. 
However, there was no difference in the frequency of 
infections in the present study. All patients of the non-
survivor group with bacterial infections eventually 
developed MSOF. Control of infections is still a major 
challenge in the ICU. In the present study, MSOF was 
the primary cause of death. Patients who do not receive 
chest compressions usually undergo a medical resuscita-
tion using potent drugs that maintain the cardiopulmo-
nary function at the expense of other organ systems such 
as the kidneys [28]. In the present study, survivors at dis-
charge had better creatinine and peak BUN levels than 
non-survivors, and a larger proportion of non-survivors 
were undergoing hemodialysis. As in the study by Grist 
et al. [20], patients sustained severe kidney damage with 
a dismal outcome, despite hemodialysis, and still lacked 
adequate renal perfusion after ECMO.
A previous study reported that age  >60  years, 
requirement of postoperative VA hemofiltration, peak 
TBIL  >102.6  µmol/L, and a need for ECPR were inde-
pendent risk factors for in-hospital mortality [29]. 
Another study reported that patients aged  >65  years, 
pH  <7.0, lactates  >12  mmol/L, creatinine  >200  µmol/L, 
or receiving ECMO under advanced life support had a 
bad prognosis [23]. However, these factors could not be 
validated in the present study, mostly because of the small 
sample size. Indeed, as a retrospective, non-randomized, 
observational study, the present study had a number of 
limitations. Although this study collected the neurologi-
cal outcome data from all patients, detailed neurologic 
examinations and neurodevelopmental evaluations were 
not recorded, as was the case in other series [19, 20, 22]. 
Many variables only showed a trend toward a difference, 
maybe due to the small sample size, which also prevented 
subgroup analyses. A larger multicenter randomized 
study is required to correctly assess the benefits of ECPR 
in patients with refractory CA after cardiac surgery. In 
addition, the etiologies of CA after cardiac surgery were 
not collected in the present study.
Similar to Kelly et  al. [15], we hypothesize that early 
ECPR and effective care are necessary to the effectiveness 
of ECMO for refractory CA after cardiac surgery. Given 
that medical and surgical complications may occur dur-
ing any phase of care, we emphasize the importance of 
multidisciplinary collaboration between professionals 
involved in the care of these patients [30]. However, a 
recent meta-analysis reported that significant morbidities 
were associated with ECMO, and that its use should be 
carefully considered based on the risk–benefit ratio [31].
Conclusions
ECPR can be successful to resuscitate adult patients fol-
lowing refractory CA after cardiac surgery. Because 
ECPR is an aggressive therapy, it is important to carefully 
select the patients for ECPR, and combine ECPR with 
IABP if necessary to improve the efficacy. Improvements 
in outcomes of patients undergoing ECPR also require a 
multidisciplinary care approach to protect organ func-
tion and limit organ injury before and during ECMO 
support. Educating ECMO staff and improving selection 
of appropriate patients for ECPR as early as possible dur-
ing CPR should contribute to an increased survival rate.
Abbreviations
ABG: arterial blood gas; ALT: alanine aminotransferase; AST: aspartate 
aminotransferase; BUN: blood urea nitrogen; CA: cardiac arrest; CK-MB: MB 
fraction of creatinine kinase; CPB: cardiopulmonary bypass; CPR: cardiopulmo-
nary resuscitation; Cr: creatinine; DBIL: direct bilirubin; ECMO: extracorporeal 
membrane oxygenation; ECPR: extracorporeal cardiopulmonary resuscita-
tion; IABP: intra-aortic balloon pump; ICU: intensive care unit; LAC: lactic acid; 
MSOF: multiple system organ failure; NYHA: New York Heart Association; TBIL: 
total bilirubin.
Authors’ contributions
YYZ carried out the study design, data collection and analysis, wrote the 
manuscript. JLX, ZTD, FL and MJ participated in data collection and help to 
perform the statistical analysis. XTH conceived of the study, and participated 
in its design and coordination and provided the critical revision. All authors 
read and approved the final manuscript.
Acknowledgements
This work was supported by grants from the National Natural Science Founda-
tion of China (Nos. 81070203 and 81270327), and Funding from the Beijing 
215 Program.
Page 7 of 7Zhao et al. Eur J Med Res  (2015) 20:83 
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 13 October 2014   Accepted: 30 September 2015
References
 1. Stiell IG, Wells GA, Field B, Spaite DW, Nesbitt LP, De Maio VJ, et al. 
Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J 
Med. 2004;351:647–56.
 2. Golding LA. Postcardiotomy mechanical support. Semin Thorac Cardio-
vasc Surg. 1991;3:29–32.
 3. Muehrcke DD, McCarthy PM, Stewart RW, Seshagiri S, Ogella DA, Foster 
RC, et al. Complications of extracorporeal life support systems using 
heparin-bound surfaces. The risk of intracardiac clot formation. J Thorac 
Cardiovasc Surg. 1995;110:843–51.
 4. Smith C, Bellomo R, Raman JS, Matalanis G, Rosalion A, Buckmaster J, et al. 
An extracorporeal membrane oxygenation-based approach to cardio-
genic shock in an older population. Ann Thorac Surg. 2001;71:1421–7.
 5. Kouwenhoven WB, Jude JR, Knickerbocker GG. Closed-chest cardiac mas-
sage. JAMA. 1960;173:1064–7.
 6. Chen YS, Chao A, Yu HY, Ko WJ, Wu IH, Chen RJ, et al. Analysis and results 
of prolonged resuscitation in cardiac arrest patients rescued by extracor-
poreal membrane oxygenation. J Am Coll Cardiol. 2003;41:197–203.
 7. Doll N, Fabricius A, Borger MA, Bucerius J, Doll S, Kramer K, et al. Tempo-
rary extracorporeal membrane oxygenation in patients with refractory 
postoperative cardiogenic shock—a single center experience. J Card 
Surg. 2003;18:512–8.
 8. Doll N, Kiaii B, Borger M, Bucerius J, Kramer K, Schmitt DV, et al. Five-year 
results of 219 consecutive patients treated with extracorporeal mem-
brane oxygenation for refractory postoperative cardiogenic shock. Ann 
Thorac Surg. 2004;77:151–7 (discussion 7).
 9. Smedira NG, Moazami N, Golding CM, McCarthy PM, Apperson-Hansen 
C, Blackstone EH, et al. Clinical experience with 202 adults receiving 
extracorporeal membrane oxygenation for cardiac failure: survival at five 
years. J Thorac Cardiovasc Surg. 2001;122:92–102.
 10. Bakhtiary F, Keller H, Dogan S, Dzemali O, Oezaslan F, Meininger D, et al. 
Venoarterial extracorporeal membrane oxygenation for treatment of 
cardiogenic shock: clinical experiences in 45 adult patients. J Thorac 
Cardiovasc Surg. 2008;135:382–8.
 11. International Liaison Committee on R. The International Liaison Com-
mittee on Resuscitation (ILCOR) consensus on science with treatment 
recommendations for pediatric and neonatal patients: pediatric basic 
and advanced life support. Pediatrics. 2006;117:e955–77.
 12. Lin JW, Wang MJ, Yu HY, Wang CH, Chang WT, Jerng JS, et al. Comparing 
the survival between extracorporeal rescue and conventional resuscita-
tion in adult in-hospital cardiac arrests: propensity analysis of three-year 
data. Resuscitation. 2010;81:796–803.
 13. Rastan AJ, Dege A, Mohr M, Doll N, Falk V, Walther T, et al. Early and late 
outcomes of 517 consecutive adult patients treated with extracorporeal 
membrane oxygenation for refractory postcardiotomy cardiogenic shock. 
J Thorac Cardiovasc Surg. 2010;139:302–11 (11 e1).
 14. Extracorporeal Life Support Organization. Registry form instruction sheet. 
2014. http://www.elsonet.org. Accessed 29 Aug 2014.
 15. Kelly RB, Harrison RE. Outcome predictors of pediatric extracorporeal 
cardiopulmonary resuscitation. Pediatr Cardiol. 2010;31:626–33.
 16. Huang SC, Yu HY, Ko WJ, Chen YS. Pressure criterion for placement of 
distal perfusion catheter to prevent limb ischemia during adult extracor-
poreal life support. J Thorac Cardiovasc Surg. 2004;128:776–7.
 17. Dalton HJ, Menon S. Extracorporeal life support during cardiac arrest 
(ECPR). In: Short BL, Williams L, editors. ECMO specialist training manual, 
3rd edn. Ann Arbor: ELSO; 2010.
 18. Jia M, Hu WL, Zhou Y, Shao JJ, Yan XL, Song TY, et al. Extracorporeal mem-
brane oxygenation support in acute cardiorespiratory function failure 
patients after cardiac surgery. Zhonghua Wai Ke Za Zhi. 2009;47:1397–9.
 19. Huang SC, Wu ET, Chen YS, Chang CI, Chiu IS, Wang SS, et al. Extracorpor-
eal membrane oxygenation rescue for cardiopulmonary resuscitation in 
pediatric patients. Crit Care Med. 2008;36:1607–13.
 20. Grist G. Extracorporeal membrane oxygenation (ECMO) or extracorpor-
eal cardiopulmonary resuscitation (ECPR): a critical life or death choice. 
Progress Ped Cardiol. 2008;24:113–6.
 21. Fiser RT, Morris MC. Extracorporeal cardiopulmonary resuscitation in 
refractory pediatric cardiac arrest. Pediatr Clin North Am. 2008;55:929–41 
(x).
 22. Lan C, Tsai PR, Chen YS, Ko WJ. Prognostic factors for adult patients 
receiving extracorporeal membrane oxygenation as mechanical circula-
tory support—a 14-year experience at a medical center. Artif Organs. 
2010;34:E59–64.
 23. Flecher E, Anselmi A, Corbineau H, Langanay T, Verhoye JP, Felix C et al. 
Current aspects of extracorporeal membrane oxygenation in a tertiary 
referral centre: determinants of survival at follow-up. Eur J Cardiothorac 
Surg. 2014;46:665–71
 24. Huang Z, Han LS, Ye J, Qiu WJ, Zhang HW, Gao XL, et al. Outcomes of 
patients with combined methylmalonic acidemia and homocystinuria 
after treatment. Zhonghua Er Ke Za Zhi. 2013;51:194–8.
 25. Ko WJ, Lin CY, Chen RJ, Wang SS, Lin FY, Chen YS. Extracorporeal mem-
brane oxygenation support for adult postcardiotomy cardiogenic shock. 
Ann Thorac Surg. 2002;73:538–45.
 26. Sajjad M, Osman A, Mohsen S, Alanazi M, Ugurlucan M, Canver C. Extra-
corporeal membrane oxygenation in adults: experience from the Middle 
East. Asian Cardiovasc Thorac Ann. 2013;21:521–7.
 27. Avalli L, Maggioni E, Formica F, Redaelli G, Migliari M, Scanziani M, et al. 
Favourable survival of in-hospital compared to out-of-hospital refrac-
tory cardiac arrest patients treated with extracorporeal membrane 
oxygenation: an Italian tertiary care centre experience. Resuscitation. 
2012;83:579–83.
 28. Lee RW, Di Giantomasso D, May C, Bellomo R. Vasoactive drugs and the 
kidney. Best Pract Res Clin Anaesthesiol. 2004;18:53–74.
 29. Wu MY, Lin PJ, Lee MY, Tsai FC, Chu JJ, Chang YS, et al. Using extracorpor-
eal life support to resuscitate adult postcardiotomy cardiogenic shock: 
treatment strategies and predictors of short-term and midterm survival. 
Resuscitation. 2010;81:1111–6.
 30. Massetti M, Gaudino M, De Paulis S, Scapigliati A, Cavaliere F. Extracorpor-
eal membrane oxygenation for resuscitation and cardiac arrest manage-
ment. Heart Fail Clin. 2014;10:S85–93.
 31. Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, Moriguchi J, et al. 
Complications of extracorporeal membrane oxygenation for treatment 
of cardiogenic shock and cardiac arrest: a meta-analysis of 1866 adult 
patients. Ann Thorac Surg. 2014;97:610–6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
